Advanced search
Publication Cover
Epigenomics Volume 3, 2011 - Issue 1
Submit an article Journal homepage
233
Views
0
CrossRef citations to date
0
Altmetric
Review

Epigenetics of Kidney Cancer And Bladder Cancer

Amanda M Hoffman1 Departments of Surgical Oncology & Pathology, W350, Fox Chase Cancer Center, 333 Cottman Avenue, Philadelphia, PA 19111, USAView further author information
&
Paul Cairns1 Departments of Surgical Oncology & Pathology, W350, Fox Chase Cancer Center, 333 Cottman Avenue, Philadelphia, PA 19111, USACorrespondence[email protected]
View further author information
Pages 19-34 | Published online: 17 Feb 2011

Bibliography

  • Jemal A , SiegelR, XuJ, WardE: Cancer statistics, 2010.CA Cancer J. Clin.60 , 277–300 (2010).
  • Cohen HT , McGovernFJ: Renal-cell carcinoma.N. Engl. J. Med.353 , 2477–2490 (2005).
  • Zambrano NR , LubenskyIA, MerinoMJ, LinehanWM, WaltherMM: Histopathology and molecular genetics of renal tumors: toward unification of a classification system.J. Urol.162 , 1246–1258 (1999).
  • Herr H , LammDL, DenisL: Management of superficial bladder cancer. In: Principles & Practice of Genitourinary Oncology. Raghavan D, Scher HL, Leibel SA, Lange PH (Eds). Lippincott-Raven, PA, USA, 273–280 (1997).
  • Cairns P , SidranskyD: Bladder Cancer, 2nd Edition. New York McGraw-Hill, NY, USA (2002).
  • Dalgliesh GL , FurgeK, GreenmanCet al.: Systematic sequencing of renal carcinoma reveals inactivation of histone modifying genes.Nature463 , 360–363 (2010).
  • Thomas RK , BakerAC, DebiasiRMet al.: High-throughput oncogene mutation profiling in human cancer.Nat. Genet.39 , 347–351 (2007).
  • Beroukhim R , BrunetJP, Di Napoli A et al.: Patterns of gene expression and copy-number alterations in von-Hippel Lindau disease-associated and sporadic clear cell carcinoma of the kidney. Cancer Res.69 , 4674–4681 (2009).
  • Hoque MO , LeeCC, CairnsP, SchoenbergM, SidranskyD: Genome-wide genetic characterization of bladder cancer: a comparison of high-density single-nucleotide polymorphism arrays and PCR-based microsatellite analysis.Cancer Res.63 , 2216–2222 (2003).
  • Jones PA , BaylinSB: The fundamental role of epigenetic events in cancer.Nat. Rev. Genet.3 , 415–428 (2002).
  • Dunn BK : Hypomethylation: one side of a larger picture.Ann. NY Acad. Sci.983 , 28–42 (2003).
  • Cui H , NiemitzEL, RavenelJDet al.: Loss of imprinting of insulin-like growth factor-II in Wilms‘ tumor commonly involves altered methylation but not mutations of CTCF or its binding site.Cancer Res.61 , 4947–4950 (2001).
  • Cui H , OnyangoP, BrandenburgS, WuY, HsiehCL, FeinbergAP: Loss of imprinting in colorectal cancer linked to hypomethylation of H19 and IGF2.Cancer Res.62 , 6442–6446 (2002).
  • Byun HM , WongHL, BirnsteinEA, WolffEM, LiangG, YangAS: Examination of IGF2 and H19 loss of imprinting in bladder cancer.Cancer Res.67 , 10753–10758 (2007).
  • Herman JG , LatifF, WengYet al.: Silencing of the VHL tumor-suppressor gene by DNA methylation in renal carcinoma.Proc. Natl Acad. Sci. USA91 , 9700–9704 (1994).
  • Dulaimi E , Ibanez de Caceres I, Uzzo RG et al.: Promoter hypermethylation profile of kidney cancer. Clin. Cancer Res.10 , 3972–3979 (2004).
  • Schmidt L , DuhFM, ChenFet al.: Germline and somatic mutations in the tyrosine kinase domain of the MET proto-oncogene in papillary renal carcinomas.Nat. Genet.16 , 68–73 (1997).
  • Tomlinson IP , AlamNA, RowanAJet al.: Germline mutations in FH predispose to dominantly inherited uterine fibroids, skin leiomyomata and papillary renal cell cancer.Nat. Genet.30 , 406–410 (2002).
  • Nickerson ML , WarrenMB, ToroJRet al.: Mutations in a novel gene lead to kidney tumors, lung wall defects, and benign tumors of the hair follicle in patients with the Birt–Hogg–Dube syndrome.Cancer Cell2 , 157–164 (2002).
  • da Silva NF , GentleD, HessonLB, MortonDG, LatifF, MaherER: Analysis of the Birt–Hogg–Dube (BHD) tumour suppressor gene in sporadic renal cell carcinoma and colorectal cancer.J. Med. Genet.40 , 820–824 (2003).
  • Gad S , LefevreSH, KhooSKet al.: Mutations in BHD and TP53 genes, but not in HNF1β gene, in a large series of sporadic chromophobe renal cell carcinoma.Br. J. Cancer96 , 336–340 (2007).
  • Ricketts C , WoodwardER, KillickPet al.: Germline SDHB mutations and familial renal cell carcinoma.J. Natl Cancer Inst.100 , 1260–1262 (2008).
  • Morris MR , HessonLB, WagnerKJet al.: Multigene methylation analysis of Wilms‘ tumour and adult renal cell carcinoma.Oncogene22 , 6794–6801 (2003).
  • Lynch HT , SmyrkTC, WatsonPet al.: Genetics, natural history, tumor spectrum, and pathology of hereditary nonpolyposis colorectal cancer: an updated review.Gastroenterology104 , 1535–1549 (1993).
  • Gylling AH , NieminenTT, Abdel-RahmanWMet al.: Differential cancer predisposition in Lynch syndrome: insights from molecular analysis of brain and urinary tract tumors.Carcinogenesis29 , 1351–1359 (2008).
  • Herman JG , UmarA, PolyakKet al.: Incidence and functional consequences of hMLH1 promoter hypermethylation in colorectal carcinoma.Proc. Natl Acad. Sci. USA95 , 6870–6875 (1998).
  • Catto JW , AzzouziAR, RehmanIet al.: Promoter hypermethylation is associated with tumor location, stage, and subsequent progression in transitional cell carcinoma.J. Clin. Oncol.23 , 2903–2910 (2005).
  • Esteller M , LevineR, BaylinSB, EllensonLH, HermanJG: MLH1 promoter hypermethylation is associated with the microsatellite instability phenotype in sporadic endometrial carcinomas.Oncogene17 , 2413–2417 (1998).
  • Esteller M , CatasusL, Matias-GuiuXet al.: hMLH1 promoter hypermethylation is an early event in human endometrial tumorigenesis.Am. J. Pathol.155 , 1767–1772 (1999).
  • Haibach H , BurnsTW, CarlsonHE, BurmanKD, DeftosLJ: Multiple hamartoma syndrome (Cowden‘s disease) associated with renal cell carcinoma and primary neuroendocrine carcinoma of the skin (Merkel cell carcinoma).Am. J. Clin. Pathol.97 , 705–712 (1992).
  • Pilarski R , EngC: Will the real Cowden syndrome please stand up (again)? Expanding mutational and clinical spectra of the PTEN hamartoma tumour syndrome.J. Med. Genet.41 , 323–326 (2004).
  • Liaw D , MarshDJ, LiJet al.: Germline mutations of the PTEN gene in Cowden disease, an inherited breast and thyroid cancer syndrome.Nat. Genet.16 , 64–67 (1997).
  • Cairns P , EvronE, OkamiKet al.: Point mutation and homozygous deletion of PTEN/MMAC1 in primary bladder cancers.Oncogene16 , 3215–3218 (1998).
  • Zysman MA , ChapmanWB, BapatB: Considerations when analyzing the methylation status of PTEN tumor suppressor gene.Am. J. Pathol.160 , 795–800 (2002).
  • Niida Y , Stemmer-RachamimovAO, LogripMet al.: Survey of somatic mutations in tuberous sclerosis complex (TSC) hamartomas suggests different genetic mechanisms for pathogenesis of TSC lesions.Am. J. Hum. Genet.69 , 493–503 (2001).
  • Rocco JW , SidranskyD: p16(MTS-1/CDKN2/INK4a) in cancer progression.Exp. Cell Res.264 , 42–55 (2001).
  • Herman JG , MerloA, MaoLet al.: Inactivation of the CDKN2/p16/MTS1 gene is frequently associated with aberrant DNA methylation in all common human cancers.Cancer Res.55 , 4525–4530 (1995).
  • Smiraglia DJ , RushLJ, FruhwaldMCet al.: Excessive CpG island hypermethylation in cancer cell lines versus primary human malignancies.Hum. Mol. Genet.10 , 1413–1419 (2001).
  • Dulaimi E , UzzoRG, GreenbergRE, Al-SaleemT, CairnsP: Detection of bladder cancer in urine by a tumor suppressor gene hypermethylation panel.Clin. Cancer Res.10 , 1887–1893 (2004).
  • Robertson KD , JonesPA: The human ARF cell cycle regulatory gene promoter is a CpG island which can be silenced by DNA methylation and down-regulated by wild-type p53.Mol. Cell Biol.18 , 6457–6473 (1998).
  • Esteller M , CornPG, BaylinSB, HermanJG: A gene hypermethylation profile of human cancer.Cancer Res.61 , 3225–3229 (2001).
  • Esteller M , SparksA, ToyotaMet al.: Analysis of adenomatous polyposis coli promoter hypermethylation in human cancer.Cancer Res.60 , 4366–4371 (2000).
  • Maruyama R , ToyookaS, ToyookaKOet al.: Aberrant promoter methylation profile of bladder cancer and its relationship to clinicopathological features.Cancer Res.61 , 8659–8663 (2001).
  • Neuhausen A , FlorlAR, GrimmMO, SchulzWA: DNA methylation alterations in urothelial carcinoma.Cancer Biol. Ther.5 , 993–1001 (2006).
  • Becker KF , AtkinsonMJ, ReichUet al.: E-cadherin gene mutations provide clues to diffuse type gastric carcinomas.Cancer Res.54 , 3845–3852 (1994).
  • Guilford P , HopkinsJ, HarrawayJet al.: E-cadherin germline mutations in familial gastric cancer.Nature392 , 402–405 (1998).
  • Grady WM , WillisJ, GuilfordPJet al.: Methylation of the CDH1 promoter as the second genetic hit in hereditary diffuse gastric cancer.Nat. Genet.26 , 16–17 (2000).
  • Kawakami T , OkamotoK, OgawaO, OkadaY: Multipoint methylation and expression analysis of tumor suppressor genes in human renal cancer cells.Urology61 , 226–230 (2003).
  • Chung WB , HongSH, KimJA, SohnYK, KimBW, KimJW: Hypermethylation of tumor-related genes in genitourinary cancer cell lines.J. Korean Med. Sci.16 , 756–761 (2001).
  • Ribeiro-Filho LA , FranksJ, SasakiMet al.: CpG hypermethylation of promoter region and inactivation of E-cadherin gene in human bladder cancer.Mol. Carcinog.34 , 187–198 (2002).
  • Reinhold WC , ReimersMA, MaunakeaAKet al.: Detailed DNA methylation profiles of the E-cadherin promoter in the NCI-60 cancer cells.Mol. Cancer Ther.6 , 391–403 (2007).
  • Stirzaker C , MillarDS, PaulCLet al.: Extensive DNA methylation spanning the Rb promoter in retinoblastoma tumors.Cancer Res.57 , 2229–2237 (1997).
  • Bachman KE , HermanJG, CornPGet al.: Methylation-associated silencing of the tissue inhibitor of metalloproteinase-3 gene suggest a suppressor role in kidney, brain, and other human cancers.Cancer Res.59 , 798–802 (1999).
  • Kagan J , SrivastavaS, BarkerPE, BelinskySA, CairnsP: Towards clinical application of methylated DNA sequences as cancer biomarkers: a joint NCI‘s EDRN and NIST workshop on standards, methods, assays, reagents and tools.Cancer Res.67 , 4545–4549 (2007).
  • Dammann R , LiC, YoonJH, ChinPL, BatesS, PfeiferGP: Epigenetic inactivation of a RAS association domain family protein from the lung tumour suppressor locus 3p21.3.Nat. Genet.25 , 315–319 (2000).
  • Dreijerink K , BragaE, KuzminIet al.: The candidate tumor suppressor gene, RASSF1A, from human chromosome 3p21.3 is involved in kidney tumorigenesis.Proc. Natl Acad. Sci. USA98 , 7504–7509 (2001).
  • Morrissey C , MartinezA, ZatykaMet al.: Epigenetic inactivation of the RASSF1A 3p21.3 tumor suppressor gene in both clear cell and papillary renal cell carcinoma.Cancer Res.61 , 7277–7281 (2001).
  • Yoon JH , DammannR, PfeiferGP: Hypermethylation of the CpG island of the RASSF1A gene in ovarian and renal cell carcinomas.Int. J. Cancer94 , 212–217 (2001).
  • Chan MW , ChanLW, TangNLet al.: Frequent hypermethylation of promoter region of RASSF1A in tumor tissues and voided urine of urinary bladder cancer patients.Int. J. Cancer104 , 611–616 (2003).
  • Lee MG , KimHY, ByunDSet al.: Frequent epigenetic inactivation of RASSF1A in human bladder carcinoma.Cancer Res.61 , 6688–6692 (2001).
  • Lee WH , MortonRA, EpsteinJIet al.: Cytidine methylation of regulatory sequences near the πι-class glutathione S-transferase gene accompanies human prostatic carcinogenesis.Proc. Natl Acad. Sci. USA91 , 11733–11737 (1994).
  • Chan MW , ChanLW, TangNLet al.: Hypermethylation of multiple genes in tumor tissues and voided urine in urinary bladder cancer patients.Clin. Cancer Res.8 , 464–470 (2002).
  • Esteller M , CornPG, UrenaJM, GabrielsonE, BaylinSB, HermanJG: Inactivation of glutathione S-transferase P1 gene by promoter hypermethylation in human neoplasia.Cancer Res.58 , 4515–4518 (1998).
  • Esteller M , HamiltonSR, BurgerPC, BaylinSB, HermanJG: Inactivation of the DNA repair gene O6-methylguanine-DNA methyltransferase by promoter hypermethylation is a common event in primary human neoplasia.Cancer Res.59 , 793–797 (1999).
  • Hoque MO , BegumS, TopalogluOet al.: Quantitative detection of promoter hypermethylation of multiple genes in the tumor, urine, and serum DNA of patients with renal cancer.Cancer Res.64 , 5511–5517 (2004).
  • Kissil JL , FeinsteinE, CohenOet al.: DAP-kinase loss of expression in various carcinoma and B-cell lymphoma cell lines: possible implications for role as tumor suppressor gene.Oncogene15 , 403–407 (1997).
  • Katzenellenbogen RA , BaylinSB, HermanJG: Hypermethylation of the DAP-kinase CpG island is a common alteration in B-cell malignancies.Blood93 , 4347–4353 (1999).
  • Gonzalgo ML , YegnasubramanianS, YanGet al.: Molecular profiling and classification of sporadic renal cell carcinoma by quantitative methylation analysis.Clin. Cancer Res.10 , 7276–7283 (2004).
  • Wethkamp N , RampU, GeddertHet al.: Expression of death-associated protein kinase during tumour progression of human renal cell carcinomas: hypermethylation-independent mechanisms of inactivation.Eur. J. Cancer42 , 264–274 (2006).
  • Tada Y , WadaM, TaguchiKet al.: The association of death-associated protein kinase hypermethylation with early recurrence in superficial bladder cancers.Cancer Res.62 , 4048–4053 (2002).
  • Christoph F , KempkensteffenC, WeikertSet al.: Methylation of tumour suppressor genes APAF-1 and DAPK-1 and in vitro effects of demethylating agents in bladder and kidney cancer.Br. J. Cancer95 , 1701–1707 (2006).
  • Marsit CJ , HousemanEA, ChristensenBCet al.: Examination of a CpG island methylator phenotype and implications of methylation profiles in solid tumors.Cancer Res.66 , 10621–10629 (2006).
  • Sathyanarayana UG , MaruyamaR, PadarAet al.: Molecular detection of noninvasive and invasive bladder tumor tissues and exfoliated cells by aberrant promoter methylation of laminin-5 encoding genes.Cancer Res.64 , 1425–1430 (2004).
  • Takahashi T , SuzukiM, ShigematsuHet al.: Aberrant methylation of Reprimo in human malignancies.Int. J. Cancer115 , 503–510 (2005).
  • Iliopoulos D , GulerG, HanSYet al.: Fragile genes as biomarkers: epigenetic control of WWOX and FHIT in lung, breast and bladder cancer.Oncogene24 , 1625–1633 (2005).
  • Kvasha S , GordiyukV, KondratovAet al.: Hypermethylation of the 5´CpG island of the FHIT gene in clear cell renal carcinomas.Cancer Lett.265 , 250–257 (2008).
  • Morris MR , GentleD, AbdulrahmanMet al.: Tumor suppressor activity and epigenetic inactivation of hepatocyte growth factor activator inhibitor type 2/SPINT2 in papillary and clear cell renal cell carcinoma.Cancer Res.65 , 4598–4606 (2005).
  • Agathanggelou A , DallolA, Zochbauer-MullerSet al.: Epigenetic inactivation of the candidate 3p21.3 suppressor gene BLU in human cancers.Oncogene22 , 1580–1588 (2003).
  • Stoehr R , WissmannC, SuzukiHet al.: Deletions of chromosome 8p and loss of sFRP1 expression are progression markers of papillary bladder cancer.Lab. Invest.84 , 465–478 (2004).
  • Marsit CJ , KaragasMR, AndrewAet al.: Epigenetic inactivation of SFRP genes and TP53 alteration act jointly as markers of invasive bladder cancer.Cancer Res.65 , 7081–7085 (2005).
  • Dahl E , WiesmannF, WoenckhausMet al.: Frequent loss of SFRP1 expression in multiple human solid tumours: association with aberrant promoter methylation in renal cell carcinoma.Oncogene26 , 5680–5691 (2007).
  • Kagara I , EnokidaH, KawakamiKet al.: CpG hypermethylation of the UCHL1 gene promoter is associated with pathogenesis and poor prognosis in renal cell carcinoma.J. Urol.180 , 343–351 (2008).
  • Urakami S , ShiinaH, EnokidaHet al.: Combination analysis of hypermethylated Wnt-antagonist family genes as a novel epigenetic biomarker panel for bladder cancer detection.Clin. Cancer Res.12 , 2109–2116 (2006).
  • de Caestecker MP , PiekE, RobertsAB: Role of transforming growth factor-β signaling in cancer.J. Natl Cancer Inst.92 , 1388–1402 (2000).
  • Roberts AB , WakefieldLM: The two faces of transforming growth factor β in carcinogenesis.Proc. Natl Acad. Sci. USA100 , 8621–8623 (2003).
  • Teicher BA : Malignant cells, directors of the malignant process: role of transforming growth factor-β.Cancer Metastasis Rev.20 , 133–143 (2001).
  • Suzuki M , ShigematsuH, ShamesDSet al.: DNA methylation-associated inactivation of TGFβ-related genes DRM/Gremlin, RUNX3, and HPP1 in human cancers.Br. J. Cancer93 , 1029–1037 (2005).
  • Okuda H , ToyotaM, IshidaWet al.: Epigenetic inactivation of the candidate tumor suppressor gene HOXB13 in human renal cell carcinoma.Oncogene25 , 1733–1742 (2006).
  • Yamada D , KikuchiS, WilliamsYNet al.: Promoter hypermethylation of the potential tumor suppressor DAL-1/4.1B gene in renal clear cell carcinoma.Int. J. Cancer118 , 916–923 (2006).
  • To KK , ZhanZ, BatesSE: Aberrant promoter methylation of the ABCG2 gene in renal carcinoma.Mol. Cell Biol.26 , 8572–8585 (2006).
  • Kawakami T , ChanoT, MinamiK, OkabeH, OkadaY, OkamotoK: Imprinted DLK1 is a putative tumor suppressor gene and inactivated by epimutation at the region upstream of GTL2 in human renal cell carcinoma.Hum. Mol. Genet.15 , 821–830 (2006).
  • Reu FJ , BaeSI, CherkasskyLet al.: Overcoming resistance to interferon-induced apoptosis of renal carcinoma and melanoma cells by DNA demethylation.J. Clin. Oncol.24 , 3771–3779 (2006).
  • Lee MG , HuhJS, ChungSKet al.: Promoter CpG hypermethylation and downregulation of XAF1 expression in human urogenital malignancies: implication for attenuated p53 response to apoptotic stresses.Oncogene25 , 5807–5822 (2006).
  • Kempkensteffen C , HinzS, SchraderMet al.: Gene expression and promoter methylation of the XIAP-associated factor 1 in renal cell carcinomas: correlations with pathology and outcome.Cancer Lett.254 , 227–235 (2007).
  • Ibanez de Caceres I , DulaimiE, HoffmanAM, Al-SaleemT, UzzoRG, CairnsP: Identification of novel target genes by an epigenetic reactivation screen of renal cancer.Cancer Res.66 , 5021–5028 (2006).
  • Agathanggelou A , BiecheI, Ahmed-ChoudhuryJet al.: Identification of novel gene expression targets for the Ras association domain family 1 (RASSF1A) tumor suppressor gene in non-small-cell lung cancer and neuroblastoma.Cancer Res.63 , 5344–5351 (2003).
  • Mori K , EnokidaH, KagaraIet al.: CpG hypermethylation of collagen type I a2 contributes to proliferation and migration activity of human bladder cancer.Int. J. Oncol.34 , 1593–1602 (2009).
  • Liang G , GonzalesFA, JonesPA, OrntoftTF, ThykjaerT: Analysis of gene induction in human fibroblasts and bladder cancer cells exposed to the methylation inhibitor 5-aza-2´-deoxycytidine.Cancer Res.62 , 961–966 (2002).
  • Suzuki H , GabrielsonE, ChenWet al.: A genomic screen for genes upregulated by demethylation and histone deacetylase inhibition in human colorectal cancer.Nat. Genet.31 , 141–149 (2002).
  • Morris MR , GentleD, AbdulrahmanMet al.: Functional epigenomics approach to identify methylated candidate tumour suppressor genes in renal cell carcinoma.Br. J. Cancer98 , 496–501 (2008).
  • Morris MR , RickettsC, GentleDet al.: Identification of candidate tumour suppressor genes frequently methylated in renal cell carcinoma.Oncogene29 , 2104–2117 (2010).
  • Seliger B , HandkeD, SchabelE, BukurJ, LichtenfelsR, DammannR: Epigenetic control of the ubiquitin carboxyl terminal hydrolase 1 in renal cell carcinoma.J. Transl. Med.7 , 90 (2009).
  • Dalgin GS , DreverM, WilliamsT, KingT, DeLisiC, LiouLS: Identification of novel epigenetic markers for clear cell renal cell carcinoma.J. Urol.180 , 1126–1130 (2008).
  • McRonald FE , MorrisMR, GentleDet al.: CpG methylation profiling in VHL related and VHL unrelated renal cell carcinoma.Mol. Cancer8 , 31 (2009).
  • Wu G , GuoZ, ChangXet al.: LOXL1 and LOXL4 are epigenetically silenced and can inhibit ras/extracellular signal-regulated kinase signaling pathway in human bladder cancer.Cancer Res.67 , 4123–4129 (2007).
  • Veerla S , PanagopoulosI, JinY, LindgrenD, HoglundM: Promoter analysis of epigenetically controlled genes in bladder cancer.Genes Chromosomes Cancer47 , 368–378 (2008).
  • Cairns P : Gene methylation and early detection of genitourinary cancer: the road ahead.Nat. Rev. Cancer7 , 531–543 (2007).
  • Teodoridis JM , HardieC, BrownR: CpG island methylator phenotype (CIMP) in cancer: causes and implications.Cancer Lett.268 , 177–186 (2008).
  • Zhang L , YuJ, WillsonJK, MarkowitzSD, KinzlerKW, VogelsteinB: Short mononucleotide repeat sequence variability in mismatch repair-deficient cancers.Cancer Res.61 , 3801–3805 (2001).
  • Esteller M : Epigenetics in cancer.N. Engl. J. Med.358 , 1148–1159 (2008).
  • Nguyen CT , WeisenbergerDJ, VelicescuMet al.: Histone H3-lysine 9 methylation is associated with aberrant gene silencing in cancer cells and is rapidly reversed by 5-aza-2´-deoxycytidine.Cancer Res.62 , 6456–6461 (2002).
  • Fraga MF , BallestarE, Villar-GareaAet al.: Loss of acetylation at Lys16 and trimethylation at Lys20 of histone H4 is a common hallmark of human cancer.Nat. Genet.37 , 391–400 (2005).
  • Ozdag H , TeschendorffAE, AhmedAAet al.: Differential expression of selected histone modifier genes in human solid cancers.BMC Genomics7 , 90 (2006).
  • Stransky N , VallotC, ReyalFet al.: Regional copy number-independent deregulation of transcription in cancer.Nat. Genet.38 , 1386–1396 (2006).
  • Seligson DB , HorvathS, McBrianMAet al.: Global levels of histone modifications predict prognosis in different cancers.Am. J. Pathol.174 , 1619–1628 (2009).
  • Ellinger J , KahlP, MertensCet al.: Prognostic relevance of global histone H3 lysine 4 (H3K4) methylation in renal cell carcinoma.Int. J. Cancer127 , 2360–2366 (2010).
  • Lamy P , AndersenCL, DyrskjotL, TorringN, OrntoftT, WiufC: Are microRNAs located in genomic regions associated with cancer?Br. J. Cancer95 , 1415–1418 (2006).
  • Saito Y , JonesPA: Epigenetic activation of tumor suppressor microRNAs in human cancer cells.Cell Cycle5 , 2220–2222 (2006).
  • Friedman JM , LiangG, LiuCCet al.: The putative tumor suppressor microRNA-101 modulates the cancer epigenome by repressing the polycomb group protein EZH2.Cancer Res.69 , 2623–2629 (2009).
  • Catto JW , MiahS, OwenHCet al.: Distinct microRNA alterations characterize high- and low-grade bladder cancer.Cancer Res.69 , 8472–8481 (2009).
  • Dyrskjot L , OstenfeldMS, BramsenJBet al.: Genomic profiling of microRNAs in bladder cancer: miR-129 is associated with poor outcome and promotes cell death in vitro.Cancer Res.69 , 4851–4860 (2009).
  • Wiklund ED , BramsenJB, HulfTet al.: Coordinated epigenetic repression of the miR-200 family and miR-205 in invasive bladder cancer.Int. J. Cancer (2010) (Epub ahead of print).
  • Jung M , MollenkopfHJ, GrimmCet al.: MicroRNA profiling of clear cell renal cell cancer identifies a robust signature to define renal malignancy.J. Cell. Mol. Med.13 , 3918–3928 (2009).
  • Nakada C , MatsuuraK, TsukamotoYet al.: Genome-wide microRNA expression profiling in renal cell carcinoma: significant down-regulation of miR-141 and miR-200c.J. Pathol.216 , 418–427 (2008).
  • Juan D , AlexeG, AntesTet al.: Identification of a microRNA panel for clear-cell kidney cancer.Urology75(4) , 835–841 (2010).
  • Banumathy G , CairnsP: Signaling pathways in renal cell carcinoma.Cancer Biol. Ther.10(7) , 658–664 (2010).
  • Battagli C , UzzoRG, DulaimiEet al.: Promoter hypermethylation of tumor suppressor genes in urine from kidney cancer patients.Cancer Res.63 , 8695–8699 (2003).
  • Friedrich MG , WeisenbergerDJ, ChengJCet al.: Detection of methylated apoptosis-associated genes in urine sediments of bladder cancer patients.Clin. Cancer Res.10 , 7457–7465 (2004).
  • Hoque MO , BegumS, TopalogluOet al.: Quantitation of promoter methylation of multiple genes in urine DNA and bladder cancer detection.J. Natl Cancer Inst.98 , 996–1004 (2006).
  • Yates DR , RehmanI, MeuthM, CrossSS, HamdyFC, CattoJW: Methylational urinalysis: a prospective study of bladder cancer patients and age stratified benign controls.Oncogene25 , 1984–1988 (2006).
  • Renard I , JoniauS, van Cleynenbreugel B et al.: Identification and validation of the methylated TWIST1 and NID2 genes through real-time methylation-specific polymerase chain reaction assays for the noninvasive detection of primary bladder cancer in urine samples. Eur. Urol.58(1) , 96–104 (2009).
  • Costa VL , HenriqueR, RibeiroFRet al.: Quantitative promoter methylation analysis of multiple cancer-related genes in renal cell tumors.BMC Cancer7 , 133 (2007).
  • Gutierrez MI , SirajAK, KhaledH, KoonN, El-RifaiW, BhatiaK: CpG island methylation in schistosoma- and non-schistosoma-associated bladder cancer.Mod. Pathol.17 , 1268–1274 (2004).
  • Breault JE , ShiinaH, IgawaMet al.: Methylation of the γ-catenin gene is associated with poor prognosis of renal cell carcinoma.Clin. Cancer Res.11 , 557–564 (2005).
  • Yates DR , RehmanI, AbbodMFet al.: Promoter hypermethylation identifies progression risk in bladder cancer.Clin. Cancer Res.13 , 2046–2053 (2007).
  • Gollob JA , SciambiCJ, PetersonBLet al.: Phase I trial of sequential low-dose 5-aza-2‘-deoxycytidine plus high-dose intravenous bolus interleukin-2 in patients with melanoma or renal cell carcinoma.Clin. Cancer Res.12 , 4619–4627 (2006).
  • Winquist E , KnoxJ, AyoubJPet al.: Phase II trial of DNA methyltransferase 1 inhibition with the antisense oligonucleotide MG98 in patients with metastatic renal carcinoma: a National Cancer Institute of Canada Clinical Trials Group investigational new drug study.Invest. New Drugs24 , 159–167 (2006).
  • Hammers HJ , VerheulH, WilkyBet al.: Phase I safety and pharmacokinetic/pharmacodynamic results of the histone deacetylase inhibitor vorinostat in combination with bevacizumab in patients with kidney cancer.J. Clin. Oncol.26, (2008) (Abstract 16094).
  • Verheul HM , SalumbidesB, van Erp K et al.: Combination strategy targeting the hypoxia inducible factor-1 α with mammalian target of rapamycin and histone deacetylase inhibitors. Clin. Cancer Res.14 , 3589–3597 (2008).
  • Shang D , LiuY, MatsuiYet al.: Demethylating agent 5-aza-2´-deoxycytidine enhances susceptibility of bladder transitional cell carcinoma to cisplatin.Urology71 , 1220–1225 (2008).
  • Costello JF , FrühwaldMC, SmiragliaDJet al.: Aberrant CpG-island methylation has non-random and tumour-type-specific patterns.Nature Genet.25 , 132–138 (2000).
  • Sjoblom T , JonesS, WoodLDet al.: The consensus coding sequences of human breast and colorectal cancers.Science314 , 268–274 (2006).
  • Aleman A , CebrianV, AlvarezMet al.: Identification of PMF1 methylation in association with bladder cancer progression.Clin. Cancer Res.14 , 8236–8243 (2008).
  • Kwabi-Addo B , ChungW, ShenLet al.: Age-related DNA methylation changes in normal human prostate tissues.Clin. Cancer Res.13 , 3796–3802 (2007).
  • Wolff EM , LiangG, CortezCCet al.: RUNX3 methylation reveals that bladder tumors are older in patients with a history of smoking.Cancer Res.68 , 6208–6214 (2008).

Reprints and Corporate Permissions

Please note: Selecting permissions does not provide access to the full text of the article, please see our help page How do I view content?

To request a reprint or corporate permissions for this article, please click on the relevant link below:

Order Reprints Request Corporate Permissions

Academic Permissions

Please note: Selecting permissions does not provide access to the full text of the article, please see our help page How do I view content?

Obtain permissions instantly via Rightslink by clicking on the button below:

Request Academic Permissions

If you are unable to obtain permissions via Rightslink, please complete and submit this Permissions form. For more information, please visit our Permissions help page.

Related research

People also read lists articles that other readers of this article have read.

Recommended articles lists articles that we recommend and is powered by our AI driven recommendation engine.

Cited by lists all citing articles based on Crossref citations.
Articles with the Crossref icon will open in a new tab.